ALN-HTT02 + Placebo
Phase 1Recruiting 0 watching 0 views this week💤 Quiet
30
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Huntington's Disease
Conditions
Huntington's Disease
Trial Timeline
Oct 14, 2024 → Jul 5, 2028
NCT ID
NCT06585449About ALN-HTT02 + Placebo
ALN-HTT02 + Placebo is a phase 1 stage product being developed by Alnylam Pharmaceuticals for Huntington's Disease. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06585449. Target conditions include Huntington's Disease.
Hype Score Breakdown
Clinical
10
Activity
5
Company
7
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06585449 | Phase 1 | Recruiting |
Competing Products
15 competing products in Huntington's Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| AFQ056 + Placebo | Novartis | Phase 2 | 52 |
| RO7234292 (RG6042) | Roche | Phase 2 | 52 |
| RG6496 + Placebo | Roche | Phase 1 | 33 |
| PF-02545920 + PF-02545920 | Pfizer | Phase 2 | 51 |
| 20 mg BID of PF-02545920 | Pfizer | Phase 2 | 51 |
| PF-02545920 + Placebo + PF-02545920 + Placebo | Pfizer | Phase 2 | 51 |
| Tetrabenazine | Lundbeck | Approved | 82 |
| BN82451B + Placebo | Ipsen | Phase 2 | 49 |
| ISIS 443139 10 mg + ISIS 443139 30 mg + ISIS 443139 60 mg + ISIS 443139 90 mg + ISIS 443139 120 mg | Ionis Pharmaceuticals | Phase 1/2 | 38 |
| WVE-120102 + Placebo | WaVe Life Sciences | Phase 1/2 | 36 |
| WVE-120101 + Placebo | WaVe Life Sciences | Phase 1/2 | 36 |
| SAGE-718 | Supernus Pharmaceuticals | Phase 3 | 72 |
| SAGE-718 + Placebo | Supernus Pharmaceuticals | Phase 2 | 47 |
| OMS643762 + Placebo | Omeros Corporation | Phase 2 | 47 |
| VX15/2503 + Placebo | Vaccinex | Phase 2 | 44 |